Langkilde, Anna Maria

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial

Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 78

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 52

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41

Herring (Clupea harengus) supplemented diet influences risk factors for CVD in overweight subjects

Lindqvist, H., Langkilde, A. M., Undeland, I., Rådendal, T., & Sandberg, A. S. (2007) · European Journal of Clinical Nutrition

Fatty Acid Research and HealthNutritional Studies and Diet

Cited by 27

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 18

244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

RAZ, I., WIVIOTT, S. D., YANUV, I., ROZENBERG, A., ZELNIKER, T. A., CAHN, A., HEERSPINK, H. L., DWYER, J. P., GOODRICH, E., BHATT, D. L., et al. (2019) · Diabetes

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 15